drugset / Trial / NCT05159050
Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis
Phase 1
Terminated
4 enrolled
Carlos Chan
Institute of Quantitative Systems Pharmacology (IQSP) · collab
NaSingle-groupOpen-labelTreatment
Summary
A first-in-human, unblinded, phase I trial of Paclitaxel-loaded tumor penetrating microparticles (TPM) in peritoneal carcinomatosis patients who are not eligible for standard-of-care therapeutic interventions.
Timeline
- Start
- 2022-04-26
- Primary completion
- 2024-03-17
- Completion
- 2025-12-09
Outcome
Outcome not reported
Stopped: “Drug supply issues”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 50 mg/m2 | Other |
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | Other |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | Other |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Other |
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | Other |